SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System ...
New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Dexcom, Inc. (NASDAQ: DXCM), a global ...
New RAMQ coverage means eligible Québec residents with type 2 diabetes on intensive insulin therapy can now access Dexcom Continuous Glucose Monitoring (CGM) to simplify diabetes management. Dexcom, ...
Dexcom G7 users have been complaining about a problem they term “goose necking” where the wire loops out of the hole on the sensor, causing the sensor to fail. Incoming CEO Jake Leach tells MD+DI the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results